- Illumina (ILMN) has received approval for four "next-generation" gene-sequencing devices that have the potential to make quicker and more accurate diagnoses of cystic fibrosis,
- The tests will search for "the largest number of cystic fibrosis gene variations that we've ever cleared a test for," the FDA's Elizabeth Mansfield said.
- Two of the tests also have potential to be used to diagnose and treat certain genetically identifiable cancers. (PR)
FDA OKs four Illumina gene-sequencing devices
Nov 20 2013, 07:22 ET